EGFR and non-small cell lung carcinoma: Argeted drugs such as erlotinib (Tarceva), afatinib (Gilotrif), gefitinib (Iressa), osimertinib (Tagrisso), and dacomitinib (Vizimpro), which inhibit EGFR tyrosine kinase activity, have been developed and approved for the treatment of NSCLC harboring EGFR mutations.